MMED logo

MiniMed Group, Inc. Stock Price

NasdaqGS:MMED Community·US$4.7b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

MMED Share Price Performance

US$17.67
-0.82 (-4.43%)
US$17.67
-0.82 (-4.43%)
Price US$17.67

MMED Community Narratives

There are no narratives available yet.

Trending Discussion

No trending discussion available.

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Good value with adequate balance sheet.

1 Risk
3 Rewards

MiniMed Group, Inc. Key Details

US$3.1b

Revenue

US$1.3b

Cost of Revenue

US$1.8b

Gross Profit

US$2.1b

Other Expenses

-US$333.0m

Earnings

Last Reported Earnings
Apr 24, 2026
Next Reporting Earnings
Sep 01, 2026
-1.19
57.06%
-10.74%
0%
View Full Analysis

About MMED

Founded
1983
Employees
8000
CEO
Que Dallara
WebsiteView website
www.minimed.com

MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company’s platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera Sync, or Guardian 4 sensor, and wraparound applications and services. It also offers CareLink, a software platform that provides support for person with diabetes, their caretakers, and HCPS. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California. MiniMed Group, Inc. operates as a subsidiary of Medtronic plc.

Recent MMED News & Updates

Seeking Alpha Jul 25

MiniMed: Next-Generation Diabetes Platform Supports A Buy Rating

Summary MiniMed Group, a Medtronic spin-off, is rated a buy with an FY 2027 price target of $19, implying 15% upside. MMED's double-digit revenue growth is driven by strong international adoption, expanding CGM attach rates, and timely product launches ahead of schedule. Despite gross margin compression and widened net losses in FY 2026, robust liquidity from IPO proceeds supports ongoing product rollouts and operational improvements. Execution and competition risks persist, but MMED's comprehensive product lineup and expanding AID market position it for sustained growth and potential multiple expansion. Read the full article on Seeking Alpha

Recent updates

No updates